482 results about "Psoriasis" patented technology

The invention discloses a difluoromethoxy phenyl PDE4 inhibitor and application thereof. The compound has the effects of resisting inflammation, treating psoriasis, treating lung injury, treating chronic obstructive pulmonary disease and the like.

The invention discloses hydrogel loaded with antibacterial polypeptide as well as a preparation method and application of the hydrogel. The preparation method of the hydrogel comprises the steps that antibacterial polypeptide and polyethylene glycol dimethacrylate are subjected to a cross-linking reaction, the hydrogel can be obtained, and the antibacterial polypeptide is obtained through polymerization synthesis of a cationic CBL monomer compound and an HBL monomer compound; the hydrogel has remarkable sterilization and anti-biofilm effects, and in-vitro cytotoxicity shows that the antibacterial polypeptide hydrogel product has no inhibition effect on normal cell growth; when the hydrogel dressing is used as a hydrogel dressing and is combined with novobiocin for use, more than 99% of antibacterial effect is achieved in a diabetes wound infection model and a fungal psoriasis infection model; and when being used as a hydrogel preparation to be combined with fluconazole, the compound has the effect of inhibiting growth of more than 99% of fungi in an animal vaginitis model.

The invention discloses a lysosome targeted chimera based on Sortilin and application thereof. The lysosome targeted chimera comprises a ligand molecule of a lysosome targeted receptor and a ligand molecule of a targeted protein to be degraded, wherein the ligand molecule and the ligand molecule are connected through a linker; the lysosome targeting receptor is Sortilin, and the ligand molecule of the lysosome targeting receptor is a polypeptide targeting the Sortilin; the protein to be degraded is membrane protein or extracellular protein. Furthermore, the polypeptide of the targeted Sortilin is connected with an enzyme response sequence and an integrin receptor targeting sequence. According to the invention, the Sortilin-combined ligand neurotensin is functionally coupled with the neutralizing antibody or polypeptide of overexpression protein in targeted tumor or inflammatory diseases, and the Sortilin-combined ligand neurotensin has obvious treatment gain in malignant solid tumor and psoriasis models. The discovery promotes the transformation potential of the lysosome participating in the biological agent, and provides a dual strategy for realizing accurate degradation through receptor recruitment and microenvironment induction.

The invention discloses application and an extraction method of prinsepia utilis royle polysaccharide, which comprises the following steps: extracting prinsepia utilis royle residues with 95% ethanol at 85 DEG C, filtering, extracting the residues with deionized water at 85-95 DEG C for 2-3 times, merging extracts, performing alcohol precipitation with 90%-95% ethanol at 2-6 DEG C, removing protein through a Sevage method, centrifugally collecting supernate, and freeze-drying to obtain the prinsepia utilis royle polysaccharide. And finally determining the content of the prinsepia utilis royle polysaccharide by using an anthrone-sulfuric acid colorimetric method, wherein the obtained prinsepia utilis royle polysaccharide is used for treating and improving skin lesion of psoriasis. Tests prove that prinsepia utilis royle polysaccharide can significantly improve psoriasis skin lesion, reduce inflammatory factor expression, enhance skin barrier function and increase expression of epidermal related protein, and is helpful for relieving symptoms of psoriasis patients and improving skin conditions.

The invention belongs to the technical field of biological medicine, and particularly relates to application of polypeptide in treatment of psoriasis. The amino acid sequence of the polypeptide provided by the invention is SEQ ID NO.1, so that the spleen-body ratio of a psoriasis mouse can be effectively reduced, and the inflammation level in the body can be reduced; the epidermal thickness of psoriasis mice and inflammatory factors in skin lesion tissues can be remarkably reduced, keratinocyte proliferation is reduced, and inflammatory factors released by inflammatory cells recruited to skin lesion positions are reduced. The polypeptide provided by the invention shows certain advantages in the aspects of relieving inflammatory response, promoting tissue repair and the like when being used for treating psoriasis. The invention provides a new method and means for treating psoriasis, and promotes the progress and development of medicine.

The invention discloses composite gel with ROS and pH dual responsiveness and a preparation method and application thereof.The preparation method comprises the steps that gold nanoparticles are prepared, gold nanostars GNS grow, a surfactant and biguanide drugs are added to obtain drug-loaded gold nanostars GM, a metal organic framework is introduced to obtain drug-loaded nanoparticles GMZ of a core-shell structure, and the composite gel is prepared. And reacting with a TSPBA solution, an astaxanthin solution and a polyvinyl alcohol PVA solution for crosslinking to obtain the ROS and pH dual responsive composite gel. According to the invention, the gold nanostars are used as a photosensitizer to construct the multifunctional composite gel, and the metal organic framework structure degrades under a slightly acidic condition of a psoriasis epithelium microenvironment to release released zinc ions, so that the gel is endowed with various treatment effects, excellent photo-thermal treatment performance and controlled release performance of the zinc ions and drugs. The gel has ROS responsiveness, can remove excessive ROS in a psoriasis microenvironment, and realizes the treatment of oxidation resistance, inflammation resistance and keratinocyte proliferation inhibition of psoriasis by combining with a nano drug delivery system.

The invention discloses an application of a polypeptide Apelin-13 in a medicine for treating psoriasis, in particular to psoriasis-like skin lesion. In an imiquimod (IMQ) cream induced mouse psoriasis model, intraperitoneal injection of Apelin-13 can significantly reduce scale, erythema and skin thickness, and can inhibit proliferation of epithelial spine cells. HE staining and immunohistochemical staining are carried out on the skin tissue of an experimental mouse, and the result shows that Apelin-13 can reduce the expression of the psoriasis marker protein K17, the thickness of the surface layer of the back side skin of the experimental mouse and the downward extension of a spinous layer. Experimental mouse serum ELISA (enzyme-linked immunosorbent assay) detection results show that the Apelin-13 can be used for down-regulating IL-17A (interleukin-17A) which is highly expressed in psoriasis. The polypeptide Apelin-13 can be used as a medicine for treating psoriasis, especially a medicine for treating psoriasis-like skin lesion.

The invention belongs to the technical field of biological medicines, and discloses application of vitamin K3 in preparation of a medicine for treating psoriasis. The invention finds that the compound vitamin K3 can obviously inhibit the activation of the STING downstream immune pathway and has an inhibition effect on the activation of the STING pathway. A mouse psoriasis model is formulated according to the absorption and metabolism characteristics of the inhibitor VK3, and it is proved that the VK3 can significantly inhibit the process of psoriasis and up-regulation of an STING pathway at an affected part in a transdermal drug delivery mode. The STING pathway does not belong to a main pathway affecting the course of disease in most non-immunodeficient inflammatory diseases, so that a better treatment effect may be generated by using the STING pathway in combination with a direct treatment drug (such as an IL-17A antibody for psoriasis). The vitamin K3 is simple in chemical structure, mature in production process and low in preparation cost, has more remarkable price advantage compared with biological agents and small-molecule targeting drugs, and has high popularization value and application prospects.

The present invention belongs to the field of traditional Chinese medicines, and particularly relates to Leixihaokang, a preparation method therefor, and use thereof. The Leixihaokang of the present invention is prepared from the following active pharmaceutical ingredients in parts by weight: 10 parts of Tripterygium glycosides and 0.1-1.3 parts of Artemisia annua extract. According to the present invention, animal experiments prove that the Leixihaokang can ameliorate renal damage in nephrotic syndrome caused by adriamycin, reduce the occurrence of proteinuria, and reduce the apoptosis of renal tissue cells. Meanwhile, the Leixihaokang of the present invention has a good inhibitory effect on renal, hepatic, splenic, and cardiac toxicity in the treatment process of nephrotic syndrome. According to the present invention, animal experiments also prove that the Leixihaokang can ameliorate skin injury in imiquimod-induced psoriasis, reduce inflammatory infiltration and alleviate skin damage. Meanwhile, the Leixihaokang has a certain degree of inhibitory effect on the hepatic and reproductive system toxicity in the treatment process of psoriasis.

The disclosure herein relates to the development and production of novel antibodies and antigen binding fragments thereof that bind TL1 A and that are useful in the treatment, prevention and diagnosis of a disease, disorder or inflammation including, for example, autoimmune diseases including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of final antibody structure being designed de novo by a computer system and its data training set without reference to a specific reference molecule.

The invention relates to a mouse model construction method for psoriasis research based on dihydroxyisobutyrylation modification of SBSN 600 site lysine. The mouse model construction method comprises the following steps: 1, constructing a plasmid comprising an SBSN gene sequence and a DNA fragment of which the 600 site of the SBSN sequence is mutated from lysine (K) to threonine (T); 2, culturing the mouse embryonic stem cells; step 3, carrying out electric transformation on the embryonic stem cells; 4, screening the medicines; 5, calling and culturing the embryonic stem cells screened in the step 4; step 6, injecting the embryonic stem cells called and cultured in the step 4 into a mouse blastocyst, then culturing the mouse blastocyst, and transplanting the cultured blastocyst into the uterus of a pseudopregnant female mouse, so that the mouse generated by delivery of the female mouse is a chimeric mouse; and 7, breeding the chimeric mouse and identifying the genotype of the mouse through PCR (Polymerase Chain Reaction).

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

Disclosed are a Pulsatilla saponin B4 derivative, a preparation method therefor, and a use thereof. A compound Pulsatilla saponin B4 (referred to as B4 or AB4) is used as a raw material, a nucleophilic substitution reaction, an electrophilic addition reaction, an esterification reaction, or an amidation reaction is separately performed on a C-19 exocyclic double bond or a C-28 carboxyl group to prepare a derivative, and the derivative is used as an active ingredient to prepare a drug having anti-inflammatory and immunomodulatory effects. In the present invention, it is disclosed for the first time that the B4 derivative has the effect of treating inflammatory diseases such as inflammatory bowel disease, atopic dermatitis, eczema, and psoriasis, and the effect is superior to that of B4 or a clinically common drug. In addition, it is also disclosed for the first time that most B4 derivatives do not show obvious cytotoxicity to macrophages, and can reduce the level of P-IκBa protein in LPS and ATP-induced macrophage NF-κB signaling pathways, inhibit the activation of NLRP3 signaling pathways and obviously reduce the level of Pro-IL-1β (p<0.05), i.e., inhibiting the activation of an inflammasome pathway, and the effect is superior to that of B4. These results show that the B4 derivative of the present invention has better anti-inflammatory activity.

The present invention relates to a traditional Chinese medicine composition for treating psoriasis, and its preparation method and use. The traditional Chinese medicine composition is prepared from the following raw materials: Portulaca oleracea, Sophora flavescens, Dictamni bark, Honeysuckle, Kochia scoparia, Phellodendron amurense, Platycladus orientalis leaves, Paeonia lactiflora, and Lithospermum officinale. The traditional Chinese medicine composition of the present invention has a scientific and reasonable formulation, synergistic efficacy, a small number of ingredients, and controlled quality. The combination of monarch, minister, adjuvant, and envoy in the present invention's formulation is scientific and reasonable. The combination of anti-inflammatory and immunomodulatory heat-clearing, blood-cooling, and antipruritic drugs can effectively eliminate the cause of the disease and enhance the antipruritic effect, exerting anti-inflammatory, antiproliferative, and local vasoconstrictive effects, with the advantages of increased efficacy and reduced toxicity, and can reduce the risk of recurrence. This promotes epithelial tissue repair, maintains the dynamic balance of skin keratinization, effectively prevents the recurrence of psoriasis, and reduces the suffering of patients.

The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.

A perilla leaf-derived nanovesicle and the use thereof in the preparation of a product with anti-inflammatory efficacy. The nanovesicle can be phagocytosed and internalized by HaCaT cells, reduce the levels of ROS and inflammatory factors in HaCaT cells, and exert an anti-inflammatory effect. Meanwhile, the nanovesicle has excellent transdermal properties, and thus can effectively alleviate and treat psoriatic dermatitis symptoms in mice. The nanovesicle can also be added as an active ingredient to different matrices to form compositions.

A method of treating mild to moderate psoriasis in a patient by administering an IL-23-specific antibody, e.g., a paleobukumab, in an initial dose and a subsequent dose in order to respond the patient to the antibody and satisfy one or more of the clinical endpoints.

Disclosed herein are antibodies and compositions used for binding to Gal3. Some embodiments allow for disrupting interactions between Galectin-3 (Gal3) and cell surface markers and / or proteins associated with neurological diseases and / or proteopathies, such as Alzheimer's disease. Additionally, disclosed herein are methods of treatment and uses of the antibodies or binding fragments thereof for the treatment of fibrosis, liver fibrosis, kidney fibrosis, cardiac fibrosis, pulmonary fibrosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, sepsis, atopic dermatitis, psoriasis, cancer, brain cancer, breast cancer, colorectal cancer, kidney cancer, liver cancer, lung cancer, pancreatic cancer, bladder cancer, stomach cancer, hematological malignancy, neurological diseases and / or proteopathies. Furthermore, some embodiments provided herein can cross the blood-brain barrier and can be conjugated or otherwise associated with one or more payloads for the treatment of a neurological disease.

Described herein are methods for treating an autoimmune or inflammatory disease in a patient, comprising administering a composition comprising: a) a plurality of antigen-major histocompatibility class II complexes (antigen-MHCIIs), each antigen-MHCII of the plurality comprising a ubiquitous autoantigen associated with a binding groove of an MHC class II molecule, wherein the ubiquitous autoantigen is chosen from PDC-E2353-367, PDC-E272-86, and PDC-E2422-436 for DRB3*0202; PDC-E2353-367, PDC-E280-94, and PDC-E2535-549 for DRB5*0101; PDC-E2629-648, PDC-E2122-135, and PDC-E2249-263 for DRB4*0101; and PDC-E2249-263 for DRB1*0801; and b) a nanoparticle core possessing a diameter of between 1 and about 100 nanometers; wherein the antigen-MHCs are coupled to the nanoparticle core or a biocompatible layer surrounding the nanoparticle core; and wherein the autoimmune or inflammatory disease is chosen from multiple sclerosis and psoriasis.

The invention discloses application of METTL1 as a target spot in preparation of a medicine for treating erythema squamous skin diseases, relates to the field of biological medicines, provides a new scheme for treatment of erythema squamous skin diseases, especially psoriasis and atopic dermatitis, relieves inflammatory response of psoriasis or atopic dermatitis by inhibiting expression of METTL1, and provides a new application of METTL1 as a target spot in preparation of medicines for treating erythema squamous skin diseases, especially psoriasis and atopic dermatitis. And erythema, scales and skin thickness are reduced.

The invention belongs to the technical field of microorganisms, and particularly relates to application of a staphylococcus epidermidis H62-3 viable bacterium preparation in preparation of a medicine for preventing or treating psoriasis. Experimental results show that the staphylococcus epidermidis H62-3 viable bacterium preparation improves skin erythema and scale symptoms of a psoriasis mouse model, remarkably reduces the skin lesion thickness, reduces the mRNA expression level of cytokines related to psoriasis at the skin lesion position of the psoriasis mouse model, and improves the psoriasis resistance of the psoriasis mouse model. And the cell factors comprise interleukin-17A, interleukin-17F and interleukin-23. The invention also discloses a preparation method of the cell factor. Therefore, the staphylococcus epidermidis H62-3 viable bacterium preparation has the prospect of being developed into the medicine for preventing or treating psoriasis.

25HC3S choline and crystalline 25HC3S choline are described in the present application. Further disclosed herein are pharmaceutical formulations of 25HC3S choline (e.g., containing crystalline 25HC3S choline) and methods of using the pharmaceutical formulations to treat or prevent diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesteremia, hypertriglyceridemia, and the like. Methods of treating fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, neurological conditions, Epstein-Barr virus associated growth, and conditions associated with fat accumulation and inflammation are provided. Also provided herein are methods of making 25HC3S, including crystalline 25HC3S choline.

The invention discloses application of pedunculoside in preparation of a medicine for treating psoriasis, and relates to the technical field of medicines. The invention provides a natural candidate drug which is clear in structure and has both effectiveness and safety for clinical treatment of psoriasis.

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.

The invention provides a novel medicine for treating psoriasis by recovering keratinocyte Pp6 and application of the novel medicine. The novel medicine has the structural formula shown in the formula (I), has the remarkable effects of inhibiting epidermal hyperplasia, reducing the infiltration number of dermal inflammatory cells and the like on a psoriasis focus area, and has the very excellent relieving or treating effect on psoriasis.

The invention discloses a pharmaceutical composition for treating psoriasis and application thereof. The active ingredient of the composition is a combination of Mongolian medicine seven-ingredient powder soup and a horse bone extracting solution, wherein the Mongolian medicine seven-ingredient powder is prepared from radix sophorae flavescentis, elecampane, fructus chebulae, szechwan chinaberry fruit, fructus gardeniae, herba violae and rhizoma picrorhizae according to a specific proportion. The preparation method of the composition mainly comprises the following steps: respectively preparing Mongolian medicine seven-component powder soup and horse bone extracting solution, and then mixing and decocting the Mongolian medicine seven-component powder soup and the horse bone extracting solution. Through the synergistic interaction of the Mongolian medicine seven-ingredient powder decoction and the horse bone extracting solution, the composition shows a treatment effect superior to that of independent use of each component in an animal model, and can remarkably relieve psoriasis-like skin lesion and down-regulate the expression of related inflammatory factors. The invention provides an application of the composition in preparation of a medicine for treating psoriasis.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a marine small molecule peptide and an active variant thereof in preparation of a medicine for treating skin diseases, the marine small molecule peptide and the active variant thereof can effectively inhibit keratinocyte pan apoptosis induced by TNF-alpha and IFN-gamma, the formation of a PANoptosome complex is blocked through a multi-target synergistic effect, and the effect of treating the skin diseases is achieved. The oxidative stress is reduced, and mitochondria is stabilized, so that a skin inflammatory cell death network is inhibited from the source. The variant has the same high sequence as the peptide, retains the activity of inhibiting cell pan-apoptosis, and has enhanced stability, skin permeability, in vivo half-life or efficacy. Based on the action mechanism, the peptide and the variant thereof can be used for preparing medicines for preventing and treating intractable skin diseases such as epidermis necrolysis, psoriasis, atopic dermatitis, skin lupus erythematosus and lichen planus. The invention also provides a composition containing the peptide or the variant thereof, and dosage forms comprise an external preparation and an injection.

The invention relates to application of oxymatrine in preparation of a medicine for treating a patient suffering from erythroderma psoriasis and the like.